Skip to content

US · NXL · MEDICAL - DEVICES

Nexalin Technology, Inc. (NXL) intrinsic value and stock valuation

$1.38as of 2026-11-21 · Mkt cap 7.49M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nexalin Technology, Inc. DCF and intrinsic value

InvestorsCraft values NXL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NXL’s statements →

Nexalin Technology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Houston, TX 77056 nexalin.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$300K+4.6% 5y CAGRd
20192025
Net income
-$-8.22M
20192025
Free cash flow
-$-4.96M
20192025
Total equity
$3.75M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$300K$170K$110K$1.32M$140K
Operating income-$-8.39M-$-7.75M-$-5.7M-$-1.83M-$-6.02M
Net income-$-8.22M-$-7.61M-$-4.65M-$-1.7M-$-6.08M
EPSd-$-501.53K-$-825.38K-$-631.79K-$-233.2K-$-835.16K
Operating cash flow-$-4.96M-$-3.94M-$-3.84M-$-2.22M-$-1.08M
Capital expenditure$0.00-$-170K-$-110K-$0.00$0.00
Free cash flow-$-4.96M-$-4.11M-$-3.94M-$-2.22M-$-1.08M
Total assets$4.64M$4.22M$3.63M$7.43M$750K
Total debt$0.00$0.00$0.00$760K$850K
Net debt-$-650K-$-570K-$-580K$590K$190K
Total equity$3.75M$3.68M$3.21M$5.48M-$-1.68M
Cash and short-term investments$3.72M$3.48M$2.95M$6.99M$660K
Income statement
20252024202320222021
Revenue$300K$170K$110K$1.32M$140K
Cost of revenue$60K$40K$30K$360K$20K
Gross profit$240K$130K$90K$960K$120K
Research and development expenses$1.08M$1.19M$1.92M$510K$140K
Selling, general and administrative expenses$7.55M$6.7M$3.86M$2.79M$6.14M
Other expenses$0.00-$0.00-$0.00-$-510K-$-140K
Operating expenses$8.63M$7.89M$5.78M$2.79M$6.14M
Cost and expenses$8.69M$7.92M$5.81M$3.15M$6.16M
Interest income$10K$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$40K$60K$80K
Depreciation and amortization$20K$20K$0.00$10K$0.00
Ebitda-$-8.2M-$-7.59M-$-4.61M-$-1.63M-$-6M
Operating income-$-8.39M-$-7.75M-$-5.7M-$-1.83M-$-6.02M
Total other income/expenses, net$170K$150K$1.05M$140K-$-60K
Income before tax-$-8.22M-$-7.61M-$-4.65M-$-1.7M-$-6.08M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.22M-$-7.61M-$-4.65M-$-1.7M-$-6.08M
Weighted average shares outstanding$16.4M$9.22M$7.36M$7.29M$7.28M
Weighted average diluted shares outstanding$16.4M$9.22M$7.36M$7.29M$7.28M
Balance sheet
20252024202320222021
Cash and short-term investments$3.72M$3.48M$2.95M$6.99M$660K
Net receivables$80K$10K$10K$0.00$20K
Inventory$130K$170K$160K$150K$30K
Total current assets$4.3M$3.96M$3.43M$7.43M$750K
Property, plant and equipment, net$0.00$0.00$0.00$10K$0.00
Goodwill and intangible assets$340K$260K$110K$0.00$0.00
Long-term investments$0.00$0.00$100K$0.00$0.00
Total non-current assets$340K$260K$200K$10K$0.00
Total assets$4.64M$4.22M$3.63M$7.43M$750K
Accounts payable$240K$160K$160K$660K$840K
Short-term debt$0.00$0.00$0.00$750K$780K
Deferred revenue$0.00$0.00$0.00$0.00$130K
Total current liabilities$890K$550K$430K$1.95M$2.36M
Long-term debt$0.00$0.00$0.00$0.00$70K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$70K
Capital lease obligations$0.00$0.00$0.00$60K$90K
Total liabilities$890K$550K$430K$1.95M$2.44M
Common stock$20K$10K$10K$10K$0.00
Retained earnings-$-92.87M-$-84.65M-$-77.04M-$-72.39M-$-70.69M
Accumulated other comprehensive income (loss)$0.00-$0.00-$0.00$40K$0.00
Total equity$3.75M$3.68M$3.21M$5.48M-$-1.68M
Total investments$3.07M$2.91M$2.46M$6.83M$0.00
Total debt$0.00$0.00$0.00$760K$850K
Net debt-$-650K-$-570K-$-580K$590K$190K
Cash flow statement
20252024202320222021
Net income-$-8.22M-$-7.61M-$-4.65M-$-1.7M-$-6.08M
Depreciation and amortization$20K$20K$0.00$0.00$0.00
Stock-based compensation$3.12M$3.56M$2.41M$270K$4.48M
Change in working capital$230K$120K-$-770K-$-630K$520K
Accounts receivable-$-70K-$0.00-$0.00$0.00-$-10K
Inventory$30K-$-20K-$-10K-$-140K-$-10K
Accounts payable$90K-$0.00-$-500K-$-190K$380K
Net cash provided by operating activities-$-4.96M-$-3.94M-$-3.84M-$-2.22M-$-1.08M
Investments in property, plant and equipment-$-100K-$-170K-$-110K$0.00$0.00
Acquisitions, net$0.00$0.00-$-100K$0.00$0.00
Net cash used for investing activities-$-130K-$-580K$4.45M-$-6.79M$0.00
Common stock issued$5.17M$4.52M$0.00$8.55M$1.43M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$5.17M$4.52M-$-200K$8.51M$1.66M
Net change in cash$80K-$-10K$420K-$-500K$580K
Cash at end of period$650K$570K$580K$160K$660K
Operating cash flow-$-4.96M-$-3.94M-$-3.84M-$-2.22M-$-1.08M
Capital expenditure$0.00-$-170K-$-110K-$0.00$0.00
Free cash flow-$-4.96M-$-4.11M-$-3.94M-$-2.22M-$-1.08M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nexalin Technology, Inc.

        Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.

        CEO
        Mark White
        Employees
        8
        Beta
        4.03

        Explore

        Frequently asked questions

        What is the intrinsic value of Nexalin Technology, Inc. (NXL)?

        InvestorsCraft does not currently publish an intrinsic value for NXL. How the IC value is calculated.

        Is NXL undervalued?

        InvestorsCraft does not publish an undervaluation signal for NXL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.